Compare CSX Corporation (CSX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs GeneDx Holdings Corp — how do they compare? CSX Corporation trades at $49.55 (market cap $92.24B), while GeneDx Holdings Corp trades at $62.25 (market cap $1.85B). The key difference: CSX Corporation is far larger — about 49.9× GeneDx Holdings Corp's market cap, and CSX Corporation pays a 1.13% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CSX | WGS | |
|---|---|---|
Market Cap | $92.24B | $1.85B |
Sector | Industrials | Technology |
52-Week High | $49.92 | $167.51 |
52-Week Low | $32.05 | $34.51 |
Enterprise Value | $110.47B | $1.85B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $49.64, up 0.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has trended down from $14.9B in 2022 to $14.1B in 2025, though net margins remain above 20%. Strong cash flow from operations supports dividends, including a recent $0.14 payout.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56.52%) and a price target near $48.87. Risks include declining revenue, high debt levels, and valuation multiples above industry norms. Earnings growth and operational efficiency gains are key catalysts for upside, but macroeconomic pressures on freight demand pose headwinds.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
